MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC
ConclusionsOur results reveals that miR-23a-3p may not only serve as a new biomarker for prognosis but also serve as a new therapeutic strategy in the RCC treatment.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Databases & Libraries | Drugs & Pharmacology | Study | Urology & Nephrology